Skip to main content
    P

    Procept Biorobotics Corp (PRCT)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $23.78
    +0.24 (+1.02%)

    Market Cap: $1.37B

    Last updated: Nov 17, 2026 at 4:38 PM ET

    Procept Biorobotics Corp (PRCT) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Procept Biorobotics (PRCT) has a market cap of $1.37B and an enterprise value of $1.20B. It kept -32.60% of revenue as net income over the last 12 months. It holds $166.60M more cash than debt, 12.17% of its market cap.

    Total Valuation

    Enterprise value is 12.17% below the market cap, as cash exceeds debt.

    Market Cap$1.37B
    Enterprise Value$1.20B
    Latest price (Nov 17, 2026)$23.78

    Key Dates

    The next earnings report is expected on Feb 23, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 23, 2027 (expected)
    Last Earnings DateNov 4, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.45% in the quarter ended Sep 30, 2026 and grew 4.99% a year over 2 years.

    Shares Outstanding57.33M
    Shares Change (YoY)+2.87%
    Shares Change (QoQ)+0.45%
    Share Count Growth (2Y CAGR)+4.99%

    Valuation Ratios

    Sales and book value multiples are 3.9x and 4.1x. Its year-end P/S ranged from 5.7x to 24.6x from 2021 to 2025.

    P/S Ratio3.9x
    Forward P/S3.5x
    P/B Ratio4.1x
    P/TBV Ratio4.2x

    Valuation history and multiples

    Price Statistics

    The stock is down 19.91% over 52 weeks and trades 21.45% above its 50-day average.

    Beta (1Y)0.97
    52-Week Change-19.91%
    1-Month Change+30.09%
    3-Month Change+8.53%
    6-Month Change-8.22%
    5-Year Change-55.07%
    Total Return (1Y)-19.91%
    Total Return (3Y CAGR)-10.40%
    Total Return (5Y CAGR)-10.34%
    Return vs SPY (1Y)-27.83%
    Max Drawdown (1Y)-53.77%
    Max Drawdown (3Y)-83.22%
    Sharpe Ratio (1Y)-0.27
    Correlation with SPY (1Y)0.20
    50-Day Average$19.58
    200-Day Average$22.85
    52-Week Range$16.66 to $38.11
    RSI (14 Days)67.9
    Average Volume (20 Days)1.34M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 5.89x current liabilities, and total debt is 0.16x shareholder equity.

    Current Ratio5.89x
    Quick Ratio4.73x
    Debt / Equity0.16x
    Interest Coverage-32.62x

    Returns and Efficiency

    Return on invested capital is -29.23% over the last 12 months, against a 5-year average of -21.99%.

    Return on Equity (ROE)-34.92%
    Return on Assets (ROA)-24.24%
    Return on Invested Capital (ROIC)-29.23%
    Return on Capital Employed (ROCE)-27.58%
    ROE (5Y Average)-30.64%
    ROA (5Y Average)-21.61%
    ROIC (5Y Average)-21.99%
    Asset Turnover0.72x
    Inventory Turnover1.57x
    Receivables Turnover3.31x
    Cash Conversion Cycle296 days

    Scores

    PRCT has an Altman Z-Score of 4.34, in the safe zone above 2.99, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score4.34
    Altman Z ZoneSafe
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $352.30M over the last 12 months is up 17.47% from the 12 months before.

    Revenue$352.30M
    Revenue Growth (YoY)+17.47%
    Gross Profit$227.79M
    Operating Income-$118.41M
    Pretax Income-$114.68M
    Net Income-$114.86M
    EBITDA-$103.29M
    EBIT-$111.27M
    Reported EPS (TTM)-$2.02

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 69.43% of the $473.76M in total assets.

    Cash and Equivalents$218.37M
    Total Debt$51.77M
    Net Cash$166.60M
    Net Cash Per Share$2.91
    Working Capital$343.84M
    Shareholder Equity$328.91M
    Book Value Per Share$5.74
    Tangible Book Value$328.41M
    Tangible Book Per Share$5.73
    Total Assets$473.76M
    Total Liabilities$144.85M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $8.38M of capital spending, operating cash flow left -$85.07M of free cash flow.

    Operating Cash Flow-$76.69M
    Capital Expenditures$8.38M
    Free Cash Flow-$85.07M
    FCF Per Share-$1.49
    Depreciation and Amortization$7.97M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -33.61%, against a 5-year average of -84.33%.

    Gross Margin64.66%
    Operating Margin-33.61%
    Pretax Margin-32.55%
    Net Margin-32.60%
    EBITDA Margin-29.32%
    EBIT Margin-31.58%
    FCF Margin-24.15%
    Gross Margin (5Y Average)54.48%
    Operating Margin (5Y Average)-84.33%
    Net Margin (5Y Average)-87.86%

    Growth

    Revenue grew 60.14% a year over 3 years.

    Revenue Growth (3Y CAGR)+60.14%
    Revenue Growth (5Y CAGR)+109.04%
    Book Value Per Share Growth (2Y CAGR)+8.43%
    Tangible Book Per Share Growth (2Y CAGR)+8.56%

    Revenue and profit by year

    Dividends and Yields

    PRCT does not pay a dividend. Its free cash flow yield is -6.24%.

    FCF Yield-6.24%
    Shareholder Yield0.00%

    Peer Position

    Against 12 similar companies, PRCT has the 5th highest P/S.

    P/S Ratio3.9x vs 1.9x median
    ROIC-29.23% vs -6.00% median
    Revenue Growth (Trailing 4 Quarters, YoY)+17.47% vs +8.90% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 24.00% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+24.00%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About PRCT

    What is PRCT's market cap?

    Procept Biorobotics has a market cap of $1.37B. Its enterprise value, which adds debt and subtracts cash, is $1.20B.

    How many shares of PRCT are outstanding?

    Procept Biorobotics has 57.33M shares outstanding. The count is up 2.87% from a year earlier.

    Does PRCT pay a dividend?

    No. Procept Biorobotics does not pay a dividend.

    How much debt does PRCT have?

    Procept Biorobotics has $51.77M of total debt and $218.37M of cash and equivalents, a net cash position of $166.60M.